Enhertu (fam-trastuzumab deruxtecan-nxki) vs Krazati (adagrasib)
Enhertu (fam-trastuzumab deruxtecan-nxki) vs Krazati (adagrasib)
Enhertu (fam-trastuzumab deruxtecan-nxki) is a targeted therapy designed to treat certain types of breast cancer that overexpress the HER2 protein, as well as other HER2-positive cancers, by combining an antibody with a chemotherapy drug. Krazati (adagrasib) is a small molecule inhibitor specifically designed to target KRAS G12C-mutated tumors, which are commonly found in non-small cell lung cancer (NSCLC) and other solid tumors. When deciding on the appropriate medication, it is crucial to consider the specific type of cancer and its genetic profile, as Enhertu is used for HER2-positive cancers while Krazati is indicated for cancers with the KRAS G12C mutation.
Difference between Enhertu and Krazati
| Metric | Enhertu (fam-trastuzumab deruxtecan-nxki) | Krazati (adagrasib) |
|---|---|---|
| Generic name | Fam-trastuzumab deruxtecan-nxki | Adagrasib |
| Indications | HER2-positive breast cancer, HER2-positive gastric or gastroesophageal junction adenocarcinoma | Non-small cell lung cancer (NSCLC) with KRAS G12C mutation |
| Mechanism of action | Antibody-drug conjugate targeting HER2 | Small molecule inhibitor targeting KRAS G12C mutation |
| Brand names | Enhertu | Krazati |
| Administrative route | Intravenous | Oral |
| Side effects | Nausea, fatigue, vomiting, alopecia, constipation, decreased appetite, anemia, neutropenia, diarrhea, leukopenia, cough, and thrombocytopenia | Diarrhea, nausea, vomiting, fatigue, abdominal pain, cough, edema, increased alanine aminotransferase, increased aspartate aminotransferase, anemia, and decreased appetite |
| Contraindications | History of interstitial lung disease, pneumonitis, hypersensitivity to fam-trastuzumab deruxtecan-nxki or excipients | None known specifically; use with caution in patients with severe hepatic or renal impairment |
| Drug class | Antibody-drug conjugate | KRAS inhibitor |
| Manufacturer | Daiichi Sankyo and AstraZeneca | Mirati Therapeutics, Inc. |
Efficacy
Enhertu (fam-trastuzumab deruxtecan-nxki) in Lung Cancer
Enhertu, also known by its generic name fam-trastuzumab deruxtecan-nxki, is a targeted therapy that has shown efficacy in treating HER2-mutant non-small cell lung cancer (NSCLC). Although initially approved for breast cancer, recent studies have demonstrated its potential in lung cancer patients with HER2 mutations, which are present in a small subset of NSCLC cases. Clinical trials have indicated that Enhertu can lead to significant tumor shrinkage and prolonged progression-free survival in patients with HER2-mutant NSCLC, offering a new treatment avenue for this group of patients.
The efficacy of Enhertu in lung cancer was highlighted in a phase II trial, where it was administered to patients with HER2-mutant NSCLC who had previously undergone treatment with other therapies. The results showed a notable objective response rate, indicating that a significant number of patients experienced tumor reduction. The duration of response and overall survival data from this trial also suggest that Enhertu provides a clinically meaningful benefit for patients with this specific type of lung cancer.
Krazati (adagrasib) in Lung Cancer
Krazati, with the generic name adagrasib, is a novel medication designed to target KRAS G12C-mutated tumors, which are prevalent in a subset of non-small cell lung cancer patients. This mutation was historically considered "undruggable," but Krazati has emerged as a promising treatment option for patients with this specific genetic alteration. In clinical trials, Krazati has demonstrated significant efficacy in shrinking tumors and controlling disease progression in patients with KRAS G12C-mutated NSCLC.
The efficacy of Krazati in lung cancer was evaluated in a phase I/II trial, where patients with advanced NSCLC harboring the KRAS G12C mutation received the drug. The findings from this study showed a robust objective response rate and a median duration of response that underscores the potential of Krazati as a targeted therapy for this challenging mutation. Furthermore, the data suggest that Krazati could offer a new hope for improved outcomes in patients with KRAS G12C-mutated lung cancer, who have limited treatment options.
Regulatory Agency Approvals
Enhertu
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Krazati
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Enhertu or Krazati today
If Enhertu or Krazati are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us